{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T14:36:59Z","timestamp":1769265419538,"version":"3.49.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Epilepsy is one of the most common childhood-onset neurological conditions with a genetic etiology. Genetic diagnosis provides potential for etiologically-based management and treatment. Existing research has focused on early-onset (&lt;24 months) epilepsies; data regarding later-onset epilepsies is limited. The goal of this study was to determine the diagnostic yield of a clinically available epilepsy panel in a selected pediatric epilepsy cohort with epilepsy onset between 24\u201360 months of life and evaluate whether this approach decreases the age of diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2). Next-generation sequencing (NGS)-based epilepsy panels, including genes associated with epileptic encephalopathies and inborn errors of metabolism (IEMs) that present with epilepsy, were used. Copy-number variant (CNV) detection from NGS data was included. Variant interpretation was performed per American College of Medical Genetics and Genomics (ACMG) guidelines. Results are reported from 211 consecutive patients with the following inclusion criteria: 24\u201360 months of age at the time of enrollment, first unprovoked seizure at\/after 24 months, and at least one additional finding such as EEG\/MRI abnormalities, speech delay, or motor symptoms. Median age was 42 months at testing and 30 months at first seizure onset; the mean delay from first seizure to comprehensive genetic testing was 10.3 months. A genetic diagnosis was established in 43 patients (20.4%). CNVs were reported in 25.6% diagnosed patients; 27.3% of CNVs identified were intragenic. Within the diagnosed cohort, 11 (25.6%) patients were diagnosed with an IEM. The predominant molecular diagnosis was CLN2 (14% of diagnosed patients). For these patients, diagnosis was achieved 12\u201324 months earlier than reported by natural history of the disease. This study supports comprehensive genetic testing for patients whose first seizure occurs \u2265 24 months of age. It also supports early application of testing in this age group, as the identified diagnoses can have significant impact on patient management and outcome.<\/jats:p>","DOI":"10.1371\/journal.pone.0255933","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T17:25:58Z","timestamp":1630517158000},"page":"e0255933","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Next-generation sequencing in childhood-onset epilepsies: Diagnostic yield and impact on neuronal ceroid lipofuscinosis type 2 (CLN2) disease diagnosis"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9203-4985","authenticated-orcid":true,"given":"Kimberly","family":"Gall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eija H.","family":"Sepp\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsi","family":"Alakurtti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotta","family":"Koskinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-379X","authenticated-orcid":true,"given":"Inka","family":"Saarinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5513-8352","authenticated-orcid":true,"given":"Akashdeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Myllykangas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juha","family":"Koskenvuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tero-Pekka","family":"Alastalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"pone.0255933.ref001","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/cge.12464","article-title":"Whole-exome sequencing broadens the phenotypic spectrum of rare pediatric epilepsy: a retrospective study","volume":"88","author":"D. A. Dyment","year":"2015","journal-title":"Clin Genet"},{"key":"pone.0255933.ref002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41525-018-0061-8","article-title":"Whole-genome analysis for effective clinical diagnosis and gene discovery in early infantile epileptic encephalopathy","volume":"3","author":"B. E. P. Ostrander","year":"2018","journal-title":"Npj Genom Medicine"},{"key":"pone.0255933.ref003","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.spen.2016.11.006","article-title":"Epilepsy in Inborn Errors of Metabolism With Therapeutic Options","volume":"23","author":"J Campistol","year":"2016","journal-title":"Semin Pediatr Neurol"},{"key":"pone.0255933.ref004","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.16448.1","article-title":"Treatment of epilepsy\u2014towards precision","volume":"7","author":"J. P. Leach","year":"2018","journal-title":"F1000research"},{"key":"pone.0255933.ref005","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/ng.2646","article-title":"Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1","volume":"45","author":"G. L. Carvill","year":"2013","journal-title":"Nature genetics"},{"key":"pone.0255933.ref006","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/epi.12954","article-title":"Diagnostic yield of genetic testing in epileptic encephalopathy in childhood","volume":"56","author":"S. Mercimek-Mahmutoglu","year":"2015","journal-title":"Epilepsia"},{"key":"pone.0255933.ref007","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jmedgenet-2015-103263","article-title":"Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis","volume":"53","author":"N. Trump","year":"2016","journal-title":"Journal of Medical Genetics"},{"key":"pone.0255933.ref008","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000448369","article-title":"Gene Panel Testing in Epileptic Encephalopathies and Familial Epilepsies","volume":"7","author":"R. S. M\u00f8ller","year":"2016","journal-title":"Molecular Syndromology"},{"key":"pone.0255933.ref009","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/gim.2015.186","article-title":"Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy","volume":"18","author":"K. L. Helbig","year":"2016","journal-title":"Genetics in Medicine"},{"key":"pone.0255933.ref010","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/epi.14074","article-title":"Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders","volume":"59","author":"A. S. Lindy","year":"2018","journal-title":"Epilepsia"},{"key":"pone.0255933.ref011","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamapediatrics.2017.1743","article-title":"Early-Life Epilepsies and the Emerging Role of Genetic Testing","volume":"171","author":"A. T. Berg","year":"2017","journal-title":"JAMA Pediatrics"},{"key":"pone.0255933.ref012","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/j.1528-1167.2012.03516.x","article-title":"Targeted next generation sequencing as a diagnostic tool in epileptic disorders","volume":"53","author":"J. R. Lemke","year":"2012","journal-title":"Epilepsia"},{"key":"pone.0255933.ref013","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/epi.12203","article-title":"Targeted capture and sequencing for detection of mutations causing early onset epileptic encephalopathy","volume":"54","author":"H. Kodera","year":"2013","journal-title":"Epilepsia"},{"key":"pone.0255933.ref014","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ejhg.2014.92","article-title":"Improving molecular diagnosis in epilepsy by a dedicated high-throughput sequencing platform","volume":"23","author":"E. D. Mina","year":"2014","journal-title":"European Journal of Human Genetics"},{"key":"pone.0255933.ref015","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pediatrneurol.2016.06.019","article-title":"Diagnostic Yield of Epilepsy Panels in Children With Medication-Refractory Epilepsy","volume":"64","author":"E. S. MD","year":"2016","journal-title":"Pediatric Neurology"},{"key":"pone.0255933.ref016","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/epi4.12055","article-title":"Gene panel analysis for nonsyndromic cryptogenic neonatal\/infantile epileptic encephalopathy","volume":"2","author":"C.-W. Fung","year":"2017","journal-title":"Epilepsia Open"},{"key":"pone.0255933.ref017","first-page":"1","author":"M. Demos","year":"2017","journal-title":"Diagnostic Yield And Treatment Impact Of Targeted Exome Sequencing In Early-Onset Epilepsy"},{"key":"pone.0255933.ref018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41525-018-0052-9","article-title":"Incorporating epilepsy genetics into clinical practice: a 360\u00b0 evaluation","volume":"3","author":"S. Oates","year":"2018","journal-title":"npj Genomic Medicine"},{"key":"pone.0255933.ref019","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000448369","article-title":"Gene Panel Testing in Epileptic Encephalopathies and Familial Epilepsies","volume":"7","author":"R. S. M\u00f8ller","year":"2016","journal-title":"Molecular Syndromology"},{"key":"pone.0255933.ref020","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nbt.1996","article-title":"Efficient targeted resequencing of human germline and cancer genomes by oligonucleotide-selective sequencing","volume":"29","author":"S. Myllykangas","year":"2011","journal-title":"Nat Biotechnol"},{"key":"pone.0255933.ref021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing","volume":"12","author":"E. Talevich","year":"2016","journal-title":"PLoS Comput Biol"},{"key":"pone.0255933.ref022","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"S. Richards","year":"2015","journal-title":"Genet Med"},{"key":"pone.0255933.ref023","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","journal-title":"Nat Methods"},{"key":"pone.0255933.ref024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nprot.2015.123","article-title":"SIFT missense predictions for genomes","volume":"11","year":"2016","journal-title":"Nat Protocols"},{"key":"pone.0255933.ref025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nmeth.2890","article-title":"MutationTaster2: mutation prediction for the deep-sequencing age","volume":"11","author":"J. Schwarz","year":"2014","journal-title":"Nat Methods"},{"key":"pone.0255933.ref026","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13052-020-00860-1","article-title":"Targeted re-sequencing for early diagnosis of genetic causes of childhood epilepsy: the Italian experience from the \u2018beyond epilepsy\u2019 project","volume":"46","author":"E. Amadori","year":"2020","journal-title":"Ital J Pediatr"},{"key":"pone.0255933.ref027","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/gm192","article-title":"Genetically complex epilepsies, copy number variants and syndrome constellations","volume":"2","author":"H. C. Mefford","year":"2010","journal-title":"Genome Med"},{"key":"pone.0255933.ref028","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/brain\/awaa171","article-title":"Epilepsy subtype-specific copy number burden observed in a genome-wide study of 17 458 subjects","volume":"143","author":"LM Niestroj","year":"2020","journal-title":"Brain"},{"key":"pone.0255933.ref029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41431-018-0244-x","article-title":"European guidelines for constitutional cytogenomic analysis","volume":"27","author":"M. Silva","year":"2019","journal-title":"Eur J Hum Genet"},{"key":"pone.0255933.ref030","first-page":"57","article-title":"Comparative study of aCGH and Next Generation Sequencing (NGS) for chromosomal microdeletion and microduplication screening","volume":"8","author":"C. D. Russo","year":"2014","journal-title":"J Prenat Medicine"},{"key":"pone.0255933.ref031","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ana.21625","article-title":"De novo STXBP1 mutations in mental retardation and nonsyndromic epilepsy","volume":"65","author":"F. F. Hamdan","year":"2009","journal-title":"Ann Neurol"},{"key":"pone.0255933.ref032","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.seizure.2016.01.006","article-title":"Effectiveness of antiepileptic therapy in patients with PCDH19 mutations","volume":"35","author":"J. Lotte","year":"2016","journal-title":"Seizure"},{"key":"pone.0255933.ref033","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejpn.2014.11.008","article-title":"Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy","volume":"19","author":"M. Trivisano","year":"2014","journal-title":"European J Paediatr Neurology Ejpn Official J European Paediatr Neurology Soc"},{"key":"pone.0255933.ref034","first-page":"280","article-title":"Loss-of-function mutations of STXBP1 in patients with epileptic encephalopathy","volume":"3","author":"Y T","year":"2016","journal-title":"Brain Dev"},{"key":"pone.0255933.ref035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-8-83","article-title":"Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases","volume":"8","author":"M. Alfadhel","year":"2013","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"pone.0255933.ref036","first-page":"412","article-title":"Everolimus for treatment-refractory seizures in TSC","volume":"8","author":"D. N. Franz","year":"2018","journal-title":"Neurology: Clinical Practice"},{"key":"pone.0255933.ref037","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.pediatrneurol.2015.05.006","article-title":"Treatment of Creatine Transporter (SLC6A8) Deficiency With Oral S-Adenosyl Methionine as Adjunct to L-arginine, Glycine, and Creatine Supplements","volume":"53","author":"J S","year":"2015","journal-title":"Pediatr Neurol"},{"key":"pone.0255933.ref038","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/1060028018822124","article-title":"Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes","volume":"53","author":"J. W. Chen","year":"2019","journal-title":"Ann Pharmacother"},{"key":"pone.0255933.ref039","first-page":"294","volume":"2","author":"D O","year":"2019","journal-title":"Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial"},{"key":"pone.0255933.ref040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40263-018-0511-y","article-title":"Treatment Strategies for Dravet Syndrome","volume":"32","author":"K. G. Knupp","year":"2018","journal-title":"Cns Drugs"},{"key":"pone.0255933.ref041","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41436-019-0512-3","article-title":"PIGT-CDG, a disorder of the glycosylphosphatidylinositol anchor: description of 13 novel patients and expansion of the clinical characteristics","volume":"21","author":"A. Bayat","year":"2019","journal-title":"Genet Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T17:26:30Z","timestamp":1630517190000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255933"}},"subtitle":[],"editor":[{"given":"Muhammad","family":"Farooq","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0255933","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}